The first clinical application of McAb in Wanle pharmaceutical, a subsidiary of Sinopharm
Time of Update: 2020-04-03
According to the information on July 18 on the website of CFDA, Shenzhen Wanle Pharmaceutical Co., Ltd., a subsidiary of CFDA, has accepted the application of class 2 therapeutic
Cooperation framework agreement signed between Yaoming biology and Anke biological needle in the development of dual anti-tumor drugs
Time of Update: 2018-12-26
According to the content of the agreement, Anke biology will use the dual anti-virus platform wuxibody with independent intellectual property rights of YaoMing biology Gamma To develop and innovate a new generation of tumor immunotherapy with bispecific antibody layout.
Important progress in research and development of antifungal agents in China
Time of Update: 2017-07-13
In recent years, due to the wide application of new treatment technologies such as anti rejection after organ transplantation and tumor intensive chemotherapy, the number of people
Development trends of PD-1 drugs in domestic pharmaceutical enterprises: the number of applications for registration has reached 15
Time of Update: 2017-07-11
PD1 / PD-L1 drugs and R & D stage declared by domestic enterprises
1.7 billion, another billion! That's what immunotherapy is all about
Time of Update: 2017-01-11
Source: biological exploration January 9, 2017, according to reports from several foreign websites, pharmaceutical giant Amgen announced to cooperate with imaging biotechnology to develop the next generation of dual-specific immunotherapy for multiple cancers.
How to resist the patent war
Time of Update: 2014-06-05
The distribution of patent applications for different indications of foreign main applicants in China is basically the same as that of Chinese patent applications in the field of antibody drugs.